Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting cellular tumor vaccines contribute to the induction of potent antitumor immune responses in murine models and patients suffering from cancers. Hepatocellular carcinoma (HCC) is one of the most frequent and malignant cancers in China. We describe, for the first time, a GM-CSF releasing vaccine strategy that represents a step toward combating this type of cancer. In this study, a bystander cell-based GM-CSF secreting vaccine against murine HCC, Hepa1-6/B78H1-GM-CSF, was co-administered with a low dose of cyclophosphamide (CY). After challenging with tumor and vaccination, immunological assays demonstrated that the cellular antitumor immune responses were efficiently activated and that tumor development was significantly retarded, which was dependent on synergy with CY. The promising outcome of the anti-HCC vaccine in the murine model demonstrates the feasibility of a future clinical application for this treatment in HCC patients.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most malignant and deadly cancers in the world; with surgical resection or liver transplantation, the clinical survival outcome is only 10%-20%, and most patients survive only 3-6 months. It is imperative that efficient, ancillary therapeutic approaches are developed to improve the clinical outcome of these patients. Of the current therapeutic possibilities, immunotherapy is the most promising candidate and can be the best adapted to current therapies. [1] [2] [3] [4] On the whole, vaccine strategies are designed to induce immune recognition of tumor cells and thus generate a sustained and potent antitumor immune response, which would be capable of eradicating tumor cells. Whole tumor cell-based vaccines, such as the granulocyte macrophage colony-stimulating factor (GM-CSF) gene-modified tumor cell vaccine (called GVAX), which has increased immunogenicity and stimulates effective tumor-specific immune responses, have recently brought about favorable preclinical and clinical results against various types of cancers. [5] [6] [7] [8] [9] [10] GM-CSF functions to stimulate proliferation, differentiation, and maturation of antigen presenting cells, such as dendritic cells (DCs) and macrophages, which results in the efficient processing and presentation of tumor associated antigens and the activation of tumor-specific cytotoxic T lymphocytes. erythroleukemia cell line, K562, which is deficient in expressing HLA class I and class II antigens, definitely contributes to a minimized allogenic rejection and thus sustained GM-CSF secretion. Such bystander cells, as shown, can produce a maximum of 1000 ng of GM-CSF/(24 h310 6 cells), and maintain a detectable level of GM-CSF production for at least 7 days after radiation. 13 In a phase I clinical trial for a vaccine against chronic myeloid leukemia, Smith et al. used K562-GM-CSF in conjunction with imatinib mesylate to treat patients with chronic phase chronic myeloid leukemia, and they found that tumor burdens in most patients were reduced. In some cases, complete molecular remissions were achieved.
14 Additionally, with the use of GM-CSF secreting bystander cells, the vaccines against different cancers may be more effective by mingling with different tumor cells, which is productively superior to autocrine tumor cells when applied to clinical use.
Previous research has shown that the generation of immune tolerance and the attenuation of tumor-specific immune responses are primarily due to the recruitment of regulatory CD4
1 CD25 1 T cells (Tregs) in the blood of cancer patients. A high number of Tregs generally leads to a poor cancer prognosis. [15] [16] [17] [18] [19] To address this issue, methods to control the effect of Tregs have been combined with vaccine treatment. This treatment is considered an ideal method for regulating the tumor environment and improving the therapeutic outcome of cancer. Some Treg-inhibiting agents have been associated with vaccine therapy, such as immune-modulating doses of chemotherapeutics, anti-CD25 or anti-GITR monoclonal antibodies. 20 It has been previously reported that low doses of cyclophosphamide (CY) combined with GVAX can abrogate the inhibitory Treg immune regulation and promote the activation of tumor-specific CD8 1 T cells. [21] [22] [23] Our study examined HCC, one of the most deadly cancers in China, with GVAX treatment, which has not been frequently used with this type of cancer. We examined the effect of this vaccine against HCC in an animal model, with the goal of moving this treatment into clinical trials. We would like to understand the preclinical value of this well-received cancer vaccine treatment before clinical use. To this end, we have collected every well-evaluated therapeutic agent used with recent GVAX therapies, including allogenic whole HCC cells, GM-CSF releasing bystander cells (B78H1) and low doses of CY. We have thoroughly assessed the curative effect and potential applicability of these vaccine combinations in this study with the goal of designing analogous cellular vaccines for clinical patients.
MATERIALS AND METHODS
Mice and tumor cell lines C57BL/6 (H-2b) mice were purchased from the Model Animal Research Center of Nanjing University. Six-to eight-week-old mice at the beginning of the experiments were used. All animal experiments were performed according to the guidelines of the National Institute of Health Guide for the Care and Use of Laboratory Animals, and approved by the Scientific Investigation Board of Nanjing Medical University (Nanjing, China). The C57BL/6 (H-2b)-derived murine melanoma cell line B78H1 (provided by Dr Jaffee at the Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital), which is deficient in MHC class I expression, and genetically modified to release GM-CSF, was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillinstreptomycin (50 U/ml), L-glutamine (2 mM) and 2-mercaptoethanol (50 mM) (complete medium), at 37 uC, with 5% CO 2 . The C57BL/6-derived murine HCC cell line Hepa1-6 was maintained in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Carlsbad, CA, USA), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 400 mg/ml G418 (Sigma, St Louis, MO, USA) with 5% CO 2 at 37 uC. Lewis lung carcinoma is a cell line established from the lung of a C57BL/6 mouse bearing a tumor that resulted from an implantation of primary Lewis lung carcinoma and was used as control.
Several monoclonal sublines of B78H1-GM-CSF were isolated by limiting dilution. The GM-CSF production of each subclone was quantified by using the following method: 1310 6 cells were plated in 5 ml of complete medium and the supernatants were collected 24 h later. Then, the mouse GM-CSF was quantified with an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA), as per the manufacturer instructions. This experiment was repeated three times.
Construction of the whole-cell GM-CSF vaccine
The whole-cell GM-CSF vaccine was composed of an even mixture of irradiated Hepa 1-6 and B78H1-GM-CSF cells. The two types of cells were harvested, washed in PBS, and irradiated at 10 000 rads using a c irradiator (Thermo Scientific, EPD Irradiator IRR-1). Proliferation of the two cell lines was then determined to assure that the vaccines could not multiply in vivo. After the optimum dose of irradiation, these two types of cells were balance mixed at a concentration of 2310 7 /ml. The irradiated B78H1-GM-CSF cells were used as a mock vaccine at a concentration of 13 10 7 /ml.
Determination of cell division
After received different doses (0, 5000, 10 000, 15 000 and 20 000 rads) of irradiation, the proliferation of B78H1-GM-CSF cells was measured by BrdU ELISA kits (Roche, Mannheim, Germany). All of the procedures were performed according to the manufacturer's instructions. The data are derived from three independent experiments.
Tumor challenge and immunizations
Five groups of C57BL/6 (H-2b) mice (n550) received a subcutaneous injection of 1310 6 /0.1 ml Hepa 1-6 cells on day 0. On day 3, the GVAX group (n510) and the GVAX1CY group (n510) were injected with whole-cell vaccines. Mice immunized with saline (n510), B78H1-GM-CSF cells only (n510) and CY only (50 mg/kg, n510) groups were treated as controls.
Identical immunizations were repeated twice at 1-week intervals. All cells used for vaccination were irradiated with 10 000 rads before injection. The length and width of the tumor mass were measured with calipers every other day, and the tumor area was represented as length (L)3width (W). Some of the tumor-bearing mice (n510) that were treated with both immune therapy and chemotherapy received a CY dose of 50 mg/kg on day 21.
Cytokine assays
The levels of IL-1b, IL-12p70, IL-6 and interferon-c (IFN-c) were determined using ELISA kits (R&D Systems). All procedures were performed following the manufacturer's instructions. The data are derived from three independent experiments.
Isolation of tumor-infiltrating lymphocytes (TILs) At certain times after vaccination, the tumors were resected and a single cell suspension was prepared by mechanical and enzymatic methods. The tumors were weighed, minced into small (1-2 mm 3 ) pieces with a scalpel, and immersed in a 10-ml enzyme cocktail containing 5% fetal bovine serum in RPMI 1640, 0.5 mg/ml collagenase A (Roche), 0.2 mg/ml hyaluronidase, type V (Sigma) and 0.02 mg/ml DNase I (Sigma) per 0.25 g of tumor tissue. The cell suspensions were filtered through 70-and 40-mm nylon mesh screens (BD Falcon, New Jersey, USA), and then, they were washed with 5% FBS in RPMI 1640. The red blood cells were lysed by brief incubation with 0.15 M ammonium chloride solution, and the cell clumps were removed by discontinuous gradient centrifugation using a Lympholyte-M gradient, as recommended by the manufacturer (Cedarlane Canada).
Cellular staining, sorting and analysis by flow cytometry For isolating DCs from the mice, the DCs were first purified from pooled spleens by density gradient centrifugation and then the cells from the low density fraction were further sorted with a FACScan flow cytometer (Becton Dickinson) for CD8 1 CD11b 2 CD11c 1 DCs. The cell purity was .95%. For detecting the phenotypic characteristics of TILs, single-cell suspensions were prepared from the isolation of TIL populations and they were incubated with anti-CD16/CD32 Fc receptor blocker for 20 min on ice, then washed and stained with CD3-FITC and CD8-PE and assayed. The antibodies and their respective isotypes, used as negative controls for surface and intracellular staining, were all purchased from BD Biosciences. The mouse regulatory T cell staining kit (eBioscience, California, USA) was used for intracellular cell staining of Foxp3, according to the instructions. The data were generated from three independent experiments. 
IFN-c ELISPOT assay
In response to antigen stimulation, the detection of antigenspecific IFN-c-secreting T cells from splenic lymphocytes or TILs immunized by GVAX was performed using ELISPOT kits (BioSource International, Camarillo, CA, USA). Briefly, 50 ml of the cell suspension from immunized or mice with a tumor burden at 10 7 cells/ml were added to each well and incubated in the presence of irradiated Hepa1-6 or LCC cells overnight at 37 uC. Lymphocytes without antigen or with 2.5 mg/ml Concanavalin A were used as a control. The IFN-c spots in the wells were then developed according to the manufacturer's instructions. All of the plates were counted on an ELISPOT reader. The results were expressed as spot-forming units per 10 6 cells after subtracting background spots. The data are derived from one experiment that is representative of a total of three independent experiments.
Cell-mediated cytotoxicity assay Splenocytes were harvested 10-14 days after the last immunization, depleted of red blood cells by hypotonic lysis, restimulated in vitro with irradiated Hepa1-6 cells at different effector/stimulator ratios, and cultured in medium that was pulsed with 50 units/ml of IL-2 for 5 days. Splenic CD8 1 T cells from mice immunized by GVAX or TILs were isolated by MACS (Miltenyi Biotec, Auburn, CA, USA), and they served as effector cells, with Hepa 1-6 as target cells. Cell-mediated cytotoxicity was determined by a non-radioactive lactate dehydrogenase (LDH) release assay (Roche), following the manufacturer's instructions. Spontaneous LDH release from either target or effector cells was subtracted from the measured values, and the final results were represented by the percentage of specific lysis, which was then calculated from LDH as follows: (experimental release-target spontaneous release-effector spontaneous release)/(target maximum release-target spontaneous release). Each experiment was performed three times, and the results were similarly aligned, so one representative experiment9s results are presented.
In vivo depletion of CD4 or CD8 T lymphocyte subsets Immunized mice were injected intraperitoneally with 500 mg of rat IgG (Abcam, Cambridge, MA, USA), anti-CD4 (clone GK1.5) and/or anti-CD8 (clone GK 2.43) on day-3 and day-1 prior to immunization with GVAX. The depletion was verified 24 h after monoclonal antibodies injection by analyzing the CD8 and CD4 T-cell populations in the blood. After treatment with monoclonal antibodies, cytotoxicity was assessed by LDH release assay.
Immunohistochemistry
Following vaccination, the tissue at the site of injection was isolated from three mice. Immunoperoxidase staining of CD4 1 and HAM 1 cells was performed on 4-mm sections of formalin-fixed paraffin-imbedded tissues. The sections were deparaffinized and subjected to heat-induced antigen retrieval using DAKO's target retrieval solution for 25 s. Following endogenous peroxidase removal using 3% hydrogen peroxide in methanol, the samples were incubated two times for 15 min each with an avidin-biotin blocking reagent (Vector, Burlingame, CA, USA) and protein-blocking reagent (DAKO, Carpinteria, CA, USA). The slides were incubated with a 1 : 80 dilution of primary antibody (anti-CD4 or HAM) or an isotype control (BD PharMingen, San Diego, CA, USA) overnight at 4 uC. The immunodetection was performed using a secondary biotinylated-polyclonal anti-Rat IgG (Sigma). Diaminobenzidine/ hydrogen peroxidase (DAKO) was used as the chromogen substrate. Serial sections were stained by routine H&E.
Statistical analysis
The data are expressed as the mean6standard error of mean, as indicated in each experiment. The comparisons between the groups were made by one-way ANOVA followed by an unpaired t-test. Version 4.0 (2005) of GraphPad Prism software was used for this purpose. Values of P,0.05 were considered significant.
The survival curves were estimated using the Kaplan-Meier method, and significance was assessed using the log-rank or the x 2 test.
RESULTS
B78H1 can stably produce an effective dose of GM-CSF in vitro As was previously described, B78H1, the MHC class I-negative allogeneic cell line, acts as an essential adjuvant in the vaccine we planned to develop, and B78H1 was modified via retroviral transduction to release GM-CSF at a dose of above 150 ng/ (24 h310 6 cells). 24 We ran flow cytometry to detect the expression of the MHC molecule and discovered that the cell line was lacking both MHC I and II molecules (Figure 1a) . Importantly, we examined the level of GM-CSF secreted by B78H1 by ELISA (Figure 1b) . As shown, the concentration of GM-CSF released varied from 100 to 1200 ng/(24 h310 6 cells), significantly increased over the concentration suggested previously. 12 Subsequently, we sought a dose of radiation (10 000 rads) that would not affect GM-CSF secretion, but that would The GM-CSF production of variant B78H1-GM-CSF cell clones was detected by ELISA. B78H1 cells were transfected with the pcDNA3.3 plasmid containing the mouse GM-CSF cDNA, as described in the section on 'Materials and methods'. B78H1-GM-CSF cells were seeded in 96-well-plates at a concentration of one cell per well. After a round of replication, the culture supernatant from eight randomly selected clones was collected and GM-CSF production was measured. (c) GM-CSF release and cell proliferation of B78H1-GM-CSF after c-irradiation. B78H1-GM-CSF cells were collected and received various doses of radiation (from 5000 to 20 000 rads). (d) GM-CSF production by B78H1-GM-CSF cells before and after freezing irradiation. The B78H1-GM-CSF cells were cultured in serum free medium (AIM-V) and were frozen in 10% DMSO and 90% FBS, then analyzed for GM-CSF production immediately after thawing. The cells received 10 000 rads either before or after freezing in the liquid nitrogen. GM-CSF production was measured as described above. (e) GM-CSF production and cell viability of irradiated B78H1-GM-CSF. Irradiated B78H1-GM-CSF cells were cultured in complete medium. The medium was refreshed every 2 days, and the GM-CSF concentration in the previous supernatant was measured by ELISA. Cell viability was also measured. Each experiment was repeated three times. ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; GM-CSF, granulocyte-macrophage colony-stimulating factor.
discontinue cell proliferation (Figure 1c ). After being frozen and thawed, the level of GM-CSF in the cell supernatant was also determined, and there was evidence that B78H1 GM-CSF secretion was not affected (Figure 1d ). Irradiated B78H1-GM-CSF was then cultured in complete medium for 2 weeks. Cell viability and the GM-CSF concentration in the supernatant were measured once every 2 days. Our results suggested that stable release of GM-CSF occurred for 6 days. Additionally, a constant cell viability was maintained (Figure 1e ). We concluded that the B78H1-GM-CSF cell line could serve as an adjuvant in our murine GVAX.
GVAX-activated potent antitumor immune responses
After 10 000 rads of radiation, GVAX that was composed of Hepa1-6 and B78H1-GM-CSF was administered subcutaneously to mice bearing HCC (n510). Fifteen days later, the spleens of the immunized mice were removed and the lymphocytes were isolated. To determine the tumor-specific immune activity of these lymphocytes, an ELISPOT assay was carried out. Irradiated Hepa1-6, at the same dose as vaccine population, was used to restimulate the lymphocytes by coculturing for 24 h. The Lewis lung carcinoma cell line was used as a negative control. After 24 h, the number of spots was counted. Each spot represented the level of IFN-c secreted by splenic lymphocytes, and demonstrated a valid and specific immunological reaction toward Hepa1-6 ( Figure 2a) . Additionally, the supernatant of the above cocultured cells was used to determine the quantitative level of IFN-c by ELISA (Figure 2b ). Splenic CD8 1 T lymphocytes were isolated and restimulated with irradiated Hepa1-6 to determine their cytotoxic effects towards viable Hepa1-6 cells or LLC. The cellmediated cytotoxicity was determined separately at ratios of 5 : 1, 20 : 1 and 50 : 1 effector (CD8 1 T cells): target (Hepa1-6 or LLC). Finally, a LDH releasing assay demonstrated that the GVAX group had a high lymphocytotoxicity (40.12%63.34%) towards Hepa1-6 cells, while failed to kill the LLC cells (Figure 2c ). Depletion of CD8 1 or CD4 1 T cells resulted in a partial loss of this activity, but the rat isotype control antibody had no effect (Figure 2d ). These results suggested that the tumor-specific CD4 1 T cells and cytotoxic T lymphocytes induced by the GVAX vaccine were both responsible for this in vivo activity.
Taken together, the above results provided convincing evidence that significant cellular immune responses had been Five groups of mice were immunized with saline, B78H1-GM-CSF, CY, GVAX and GVAX1CY and were killed 15 days after immunization. Splenic lymphocytes were isolated and cocultured with irradiated Hepa1-6 or LLC for 24 h. IFN-c produced by the splenic lymphocytes was measured by an ELISPOT assay and ELISA. (c) Cytotoxicity of splenic CD8 1 T lymphocytes measured by LDH releasing assay. After the mice were sacrificed, splenic CD8 1 T lymphocytes were isolated by magnetic beads to be analyzed for cytotoxicity against Hepa1-6 or LLC cells after restimulation with irradiated Hepa1-6. (d) Cytotoxicity of splenocytes with CD8 or CD4 depletion. Lymphocytotoxicity against Hepa1-6 was been inhibited by anti-CD4 and CD8 antibody treatments. The data are from one experiment that is representative of a total of three separate experiments. CY, cyclophosphamide; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; LDH, lactate dehydrogenase; LLC, Lewis lung carcinoma.
Bystander cell-based GM-CSF secreting vaccine C Chen et al elicited by the administration of GVAX in a tumor-specific and CD8-dependent manner.
GVAX enhanced the antigen-presenting ability of DCs in vivo
The principal immunological function of GM-CSF has been shown to affect the function of antigen presenting cells, particularly DCs, which play an important role in the priming of naive CD4 1 and CD8 1 T cells. Based on the efficient GM-CSF release by B78H1-GM-CSF, we wanted to investigate whether DCs served as the intermediary between GM-CSF and T cells postvaccination in vivo. After the last immunization, splenocytes were isolated and sorted or analyzed by flow cytometry. The absolute numbers of CD11c 1 DCs in the spleen were equivalent before and after immunization (Figure 3a) . GVAX was able to upregulate the expression of CD80, CD86, CD40, MHC-I H2-K b and MHC-II (Figure 3b) , compared with the control group. However, GVAX-stimulated DCs secreted more IL-12, IL-6 and IL-1b when stimulated with lipopolysaccharide (LPS) (Figure 3c ). Furthermore, CD11c
1 DCs isolated from GVAX immunized mice had significantly enhanced Th1 cell activation and proliferation than in the control mice (Figure 3d ), confirming that GVAX enhanced DC maturation and presentation in vivo.
GVAX synergized with low doses of CY inhibited tumor growth Next, we investigated the effect of CY incorporation in GVAX therapy on tumor suppression. The murine HCC model, which is an allogenic subcutaneous grafted tumor model, was constructed through subcutaneous injection of the Hepa1-6 cell line. After challenging with tumor, the C57BL/6 mice received a low dose of CY (50 mg/kg) 1 day before vaccination with irradiated GVAX. To identify the combined antitumor effects of the two therapeutic agents, control groups were set up such that a number of tumor bearing mice were only given immunotherapy or chemotherapy. The GVAX vaccine visibly arrested tumor growth and prolonged the longevity of tumor bearing mice. Furthermore, treatment with a synergizing dose of CY before vaccination efficiently enhanced the antitumor effect of GVAX. The tumor suppression and tumor survival of each group is described below (Figure 4a and b) . The tumor burden of mice treated with both therapeutic agents was most reduced among all of the groups, adding to the evidence that the antitumor effects of a vaccine with chemotherapy are superior to the vaccine alone.
The recall response of the memory T cells was examined by injection of the vaccinated animals with Hepa1-6 cells. The eight mice that had survived beyond week 5 after hepatic tumor challenge and treatment with GVAX1CY were then rechallenged with subcutaneous tumor, as described. Six of the eight mice were fully protected from tumor growth, and two had minimal tumor growth. However, all of the naive mice (n56) had vigorous tumor growth (Figure 4c ). This finding was statistically significant at both 24 and 27 days (P,0.05 for both). We concluded that irradiated GVAX could efficiently elicit an antitumor memory immune response in vivo.
GVAX combined with a low dose of CY induced a higher percentage of CD8
1 T cells and fewer Tregs We also detected the TILs content in the mice. After tumor challenge, C57BL/6 mice received a low dose of 50 mg/kg CY 1 day before vaccination with irradiated GVAX. The TILs were separated from the tumor, as described in the section on 'Materials and methods'. As is demonstrated in Figure 5a , the GVAX1CY group triggered the most CD3
1 TILs. CD8 1 TILs accounted for 11% of the cells and the Tregs were at less than 3% (Figure 5b and c) . Overall, GVAX combined with CY or not did enhance tumor-specific cytotoxicity, but it did downregulate Treg immune suppression. To evaluate whether the TILs exhibited a specific response to the target cells, we measured the cytolytic activity of the sorted CD8
1 TILs in various groups. The results indicated that the GVAX1CY group exhibited the highest level of cytolytic activity against target cells, with the GVAX group having the second most activity (Figure 5d ). To confirm this finding, we used the TILs to perform an IFN-c ELISPOT to detect secretion. The ELISPOT results demonstrated that the TILs from the GVAX1CY and GVAX groups contained a greater number of IFN-c secreting spots compared to the control groups (Figure 5e ). This finding indicated that the GVAX with or without CY immunization potently disrupts tolerance in the tumor microenvironment.
Local inflammation and immune status after vaccination
To investigate the inflammatory state of the injection site after GVAX vaccination, pathological examination of the local tissue was conducted on the vaccinated mice. Immunized mice were euthanized 14 days after vaccination and the indicated organs (spleen and liver) were harvested. H&E staining indicated that inflammation was induced; we found that few neutrophils and erythrocytes infiltrated the hepatic cords, but did not disrupt the liver lobular structures. The spleens were slightly swollen, but there was no structural disorder or necrosis (Figure 6a) . Additionally, immunohistochemistry was performed 7 days after the last vaccination, and the results demonstrated that the GVAX group recruited more T cells to the tumor area than the others, as illustrated in the graph (Figure 6b ). The integrated optical density value was measured by Image-Pro Plus 6.0 (Figure 6c) . Collectively, the above findings offer evidence that the murine HCC vaccine Hepa1-6/B78H1-GM-CSF, which combined newly developed vaccine agents, had great potential for anti-HCC immunity.
DISCUSSION
HCC is one of the most malignant cancers in the world and is increasing in prevalence due to chronic infections with hepatitis B or C viruses. Immune-based therapies are a novel anti-cancer strategy that has shown potent antitumor activity in HCC subjects. The main goal of this strategy is to achieve cellular immunity toward tumor cells; specifically, the goal of HCC immunotherapy is to prime a tumor-specific cytotoxic immune response by uniting effective immunological agents and other therapeutic approaches.
Within the past decades, genetically modified, GM-CSF releasing cell-based vaccines have been widely studied and deeply understood. More research is needed to move them to clinical use for their superiority than other immunological agents. This cellular tumor vaccine produces an effective local concentration of GM-CSF and maintains antitumor immune responses. Moreover, it has previously been reported that a level of GM-CSF up to 360 ng/(24 h310 6 cells) may cause no reduction in vaccine responses. 25 Nevertheless, it has been argued that high-dose GM-CSF-producing vaccines fail to potentiate antitumor immunity and, instead, lead to an increase in myeloid-derived suppressor cells, which may reduce the cytotoxicity of T lymphocytes that target tumor cells. 26 Since then, it has been demonstrated that a GM-CSF concentration of 300 ng/(24 h310 6 cells) will maximize the activation of tumor-specific T cells. While conceding the fact that increasing dependency on this adjuvant may be negative, we selected a subclone of B78H1 that released GM-CSF at an optimal level as the ideal bystander cell in our cellular vaccine. While the functional effect of GM-CSF is still under exploration, we seek to fully understand the mechanism behind the immunological effects.
T cells play a critical role in tumor immunity. There has been much attention to CD4
1 T cells in antitumor responses in recent years. Studies have found that CD4 1 T cells can kill the tumor cells directly, similar to CD8 1 T cells. 27 Activated CD41 T cells also can secret interlukin-4 and interleukin-5 to accelerate the activation, differentiation and antibody formation of B lymphocytes. 28, 29 Some experiments have demonstrated that IFN-c was responsible for the inhibition of tumor induced angiogenesis and could prevent tumor growth by inducible nitric oxide synthase (iNOS). iNOS is an enzyme that is responsible for the production of NO, an important molecule used by macrophages to kill abnormal cells. 30, 31 Hahn et al. 32 reported that activated CD4 1 T cells from mice that did not express perforin could not kill Fas and Fas 1 positive target cells, so they suggested that the perforin induced pathway was the mechanistic basis for the CD4 1 T cell killing effect. Other research has suggested that BALB/C mice depleted of Th cells still retained an intensive antitumor response, but this effect was maintained for a reduced amount of time. 33 Our studies have also demonstrated an important role for CD4
1 T cells in GVAX vaccination. It has been widely accepted that DCs are the most efficient antigen presenting cells in priming both CD4
1 and CD8 1 T cells. In our experiments, DCs stimulated by GVAX could promote the activation of Th1 cells through the upregulation of MHC I and II molecules and through the enhanced secretion of cytokines (IL-12, IL-6, IL-1b), resulting in a specific anti-HCC response.
Immune tolerance results from a failure to prime and sustain tumor-specific immunity, which is attributed to the suppression by Tregs. It has been demonstrated that chemotherapeutic agents, such as CY, can ameliorate the antitumor effect of tumor vaccines due to immune tolerance. 34 Additionally, the dose range and administration schedule of chemotherapy directly affects the combined therapeutic effect. 22 There is little doubt that a high dose of chemotherapy can also depress the immune system, resulting is a weakened tumor-specific T-cell response. However, a low dose of chemotherapy will augment the immunological effects of tumor vaccines. 35 Low doses of CY enhanced T helper type 1-mediated immunity, promoted DC activation and cytokine secretion (such as IFN-c), and most importantly, eliminated a large number of regulatory T cells, which caused immune tolerance toward tumor cells. As was suggested previously, we carried out the auxiliary chemotherapy regimen 1 day before administering Hepa1-6/B78H1-GM-CSF, which should have been the most therapeutically relevant time, and used the effective dose range of 50-150 mg/kg. 22 Furthermore, ELISPOT assays and cytotoxicity assays in our study demonstrated that the infiltrating T cells had stronger, specific antitumor effects. The chemotherapy used in clinical HCC patients has not received extremely promising outcomes recently, yet as an ancillary strategy, it may be a more useful therapeutic.
The abilities of immigration to the tumor area and cytotoxic effect from abundant tumor special or non-special effective cells were attributed to a successful immune therapy. To evaluate the specific and nonspecific immune responses elicited by the vaccine Hepa1-6/B78H-GM-CSF, several experiments were * Figure 4 The MHC class I negative bystander cell B78H1-GM-CSF retains an antitumor protective function. C57BL/6 (H-2b) mice were challenged subcutaneously by 10 6 Hepa1-6 cells and vaccinated 3 days later with a Hepa1-6 (10 6 ) and B78H1-GM-CSF (10 6 ) mixture that was irradiated with 10 000 rads. The mice were measured every other day for the development of tumors. (a, b) The tumor area and percent of tumor free mice that were vaccinated with saline, B78H1-GM-CSF, CY, GVAX and GVAX1CY are shown. (c) The difference in the tumor area of naive and treated groups were assessed by tumor rechallenge. Survivors from the GVAX1CY group were rechallenged with Hepa1-6 cells 80 days after the primary tumor inoculation. Agematched naive mice were used as controls (n56). P values were calculated in comparison with the non-vaccinated group. *P,0.05. CY, cyclophosphamide; GM-CSF, granulocyte-macrophage colony-stimulating factor.
conducted. Immunohistochemical staining of immunocyte markers CD4, CD8 and CD68 were performed with skin tissue from injection site, and regular H&E staining of the skin, liver and spleen was performed to measure systematic immune conditions. The results demonstrated that the Hepa1-6/B78H1-GM-CSF vaccine could recruit a large number of lymphocytes and macrophages compared to the other groups. The tumor-specific cytotoxicity tests showed that GVAX strongly facilitated an antitumor effect, but did not impair the common cells. In H&E-stained slices, neutrophils were primarily observed in the hepatic cord that was close to the central vein in the liver and lymphoid follicles, which indicated that a systematic response was triggered, but this response was not strong enough to damage the human body. Overall, GVAX increased systematic, nonspecific immunity and enhanced the tumor-specific killing effect, both of which ensured that GVAX was an effective and safe therapy. 1 T cells from TILs after incubation with Hepa1-6 overnight) and target cells were incubated in a 0.2-ml culture volume of a 96-well culture plate at a ratio of E/T51 : 10. The cells were cocultured for 18 h, and the supernatant was harvested. The LDH levels were measured by a kit, as described in the section on 'Materials and methods'. (e) An ELISPOT assay of the TILs from vaccinated mice. Standard IFN-c ELISPOT assays were developed according to the kit manual. Mice vaccinated with GVAX or GVAX1CY demonstrated significantly more spot-forming colonies than the controls. *P,0.05, **P,0.01 and ***P,0.001 versus the saline vaccination group. Each experiment was performed three times, and the results are approximations. CY, cyclophosphamide; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; LDH, lactate dehydrogenase; TIL, tumor-infiltrating lymphocyte.
In conclusion, this study of a GM-CSF producing cellular vaccine against murine HCC, which demonstrated a positive therapeutic effect, has provided abundant evidence that it is has potential for clinical use in HCC patients. The nonspecific immune response at injection site was detected by immunohistochemistry. Local skin tissue at the injection site was separated 7 days after vaccination. CD4 and CD8 were used as markers for T cells, while CD68 was used for macrophages.
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Comparison between the vaccinated and the control group (n55) was performed by Image-Pro Plus software (version 6.0) (Media Cybernetics, Inc., Bethesda, MD, USA). Arrows indicate tumor site (9), inflammatory site (9); **P,0.01.
